ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5

Can Yue¹, Weiliang Song², Lei Wang³, Fanchong Jian⁴, Xiaosu Chen³, Fei Gao⁵, Zhongyang Shen⁶, Youchun Wang⁷, Xiangxi Wang⁸, Yunlong Cao⁹

Affiliations

¹ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Changping Laboratory, Beijing 100871, China.
² Changping Laboratory, Beijing 100871, China; Biomedical Pioneering Innovation Center, Peking University, Beijing, China; School of Life Sciences, Peking University, Beijing, China.
³ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
⁴ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Changping Laboratory, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
⁵ Frontier Research Center for Cell Response, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China; Department of Pulmonary and Critical Care Medicine, The Fourth Hospital of Inner Mongolia, Hohhot, China.
⁶ Organ Transplant Center, National Health Commission Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
⁷ Changping Laboratory, Beijing 100871, China; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.
⁸ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Changping Laboratory, Beijing 100871, China. Electronic address: xiangxi@ibp.ac.cn.
⁹ Changping Laboratory, Beijing 100871, China; Biomedical Pioneering Innovation Center, Peking University, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 36746173
PMCID: PMC9897732
DOI: 10.1016/S1473-3099(23)00010-5

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5

Can Yue et al. Lancet Infect Dis. 2023 Mar.

. 2023 Mar;23(3):278-280.

doi: 10.1016/S1473-3099(23)00010-5. Epub 2023 Feb 3.

Authors

Can Yue¹, Weiliang Song², Lei Wang³, Fanchong Jian⁴, Xiaosu Chen³, Fei Gao⁵, Zhongyang Shen⁶, Youchun Wang⁷, Xiangxi Wang⁸, Yunlong Cao⁹

Affiliations

¹ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Changping Laboratory, Beijing 100871, China.
² Changping Laboratory, Beijing 100871, China; Biomedical Pioneering Innovation Center, Peking University, Beijing, China; School of Life Sciences, Peking University, Beijing, China.
³ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
⁴ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Changping Laboratory, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
⁵ Frontier Research Center for Cell Response, Institute of Immunology, College of Life Sciences, Nankai University, Tianjin, China; Department of Pulmonary and Critical Care Medicine, The Fourth Hospital of Inner Mongolia, Hohhot, China.
⁶ Organ Transplant Center, National Health Commission Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
⁷ Changping Laboratory, Beijing 100871, China; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.
⁸ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; Changping Laboratory, Beijing 100871, China. Electronic address: xiangxi@ibp.ac.cn.
⁹ Changping Laboratory, Beijing 100871, China; Biomedical Pioneering Innovation Center, Peking University, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 36746173
PMCID: PMC9897732
DOI: 10.1016/S1473-3099(23)00010-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

YC is a cofounder of Singlomics Biopharmaceuticals and inventor of provisional patents associated with SARS-CoV-2 neutralising antibodies, including SA55 and SA58. All other authors declare no competing interests. CY and WS contributed equally.

Figures

**Figure**
Comparison of antibody evasiveness and hACE2 binding affinity of XBB.1 and XBB.1.5 (A) NT₅₀ against SARS-CoV-2 B.1 (Asp614Gly), XBB.1, and XBB.1.5 pseudovirus using plasma from patients with BA.1 (n=50), BA.5 (n=36), or BF.7 (n=30) breakthrough infection convalescents who had received three doses of CoronaVac, and those with a BA.5 breakthrough infection convalescents who had received three or four vaccinations, including at least two doses of mRNA vaccines (BNT162b2 or mRNA-1273; n=10). p values were calculated using two-tailed Wilcoxon signed rank tests. (B) Pseudovirus IC₅₀ of therapeutic neutralising antibodies. (C) Surface plasmon resonance sensorgrams measuring the hACE2-binding affinity of SARS-CoV-2 BQ.1.1, XBB and XBB.1, and XBB.1.5 receptor-binding domain. Surface plasmon resonance data were fitted to a 1:1 binding model using Biacore 8K Evaluation Software (version 3.0.12; Cytiva, Uppsala, Sweden). All neutralisation assays were done in at least two independent experiments. hACE2=human ACE2. IC₅₀=50% inhibition concentration. k_a=fitted association rate constant. k_d=fitted dissociation rate constant. K_D=dissociation equilibrium constant. *10 000 was the upper limit of detect; these analyses gave values more than 10 000.

See this image and copyright information in PMC

References

1. US Centers for Disewase Control and Prevention COVID Data Tracker. 2023. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
1. Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022 doi: 10.1038/s41586-022-05644-7. published online Dec 19. - DOI - PMC - PubMed
1. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022 doi: 10.1038/s41591-022-02162-x. published online Dec 6. - DOI - PubMed
1. Jiang X-L, Zhu KL, Wang XJ, et al. Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection. Lancet Infect Dis. 2023;23:28–30. - PMC - PubMed
1. Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23:30–32. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5

Affiliations

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5

Authors

Affiliations

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources